Novo Nordisk Balances Canadian Price Pressure With Sickle Cell Advance and Oral Pill Triumph

Novo Nordisk has clawed back roughly 31 percent from its March low, riding a wave of clinical data from the European Congress on Obesity in Istanbul that has refocused attention on its metabolic pipeline. Yet beneath the rally lies a growing threat to the company's lucrative semaglutide franchise — one that emerged thousands of kilometres from the conference floor.

Canada became the first G7 country to approve a generic version of semaglutide, clearing an entry from India's Dr. Reddy's. A second copy from Apotex quickly followed, and seven more applications are under review. The financial risk is stark: once three generics hit the market, Canadian law mandates a 65 percent price discount. Canada ranks as Novo Nordisk's second-largest market for the drug class.

The Danish drugmaker is fighting back with own-branded generics at lower prices. Regulators have already approved Plosbrio and Poviztra. In India, competitors launched copycat versions as early as the first quarter.

Meanwhile, the Istanbul congress has given investors plenty of reasons to look past the patent cliff. Novo presented 52 scientific abstracts, headlined by a higher-dose formulation of Wegovy containing 7.2 milligrams of semaglutide. Patients who had lost at least 15 percent of their body weight after 24 weeks went on to achieve an average 27.7 percent reduction by week 72. Across the entire study group, the average weight loss stood at roughly 21 percent — a meaningful jump from the 17 percent delivered by the standard 2.4 milligram dose. Novo stressed that the 27.7 percent figure applies only to early responders, making a direct comparison with rival products inappropriate.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The real surprise came in quarterly sales figures for the oral version of Wegovy. During its first full quarter on the US market, the pill generated around 2.26 billion Danish kroner in revenue — nearly double what analysts had forecast. All three major US pharmacy benefit managers have added the tablet to their standard formularies, putting it on equal footing with the injectable. Wegovy now commands roughly 65 percent of new prescriptions for obesity medications in the US. Eli Lilly has countered since April with its own oral pill, Foundayo.

Citi responded by raising its price target to 290 Danish kroner while maintaining a "Neutral" rating, estimating 2026 annual pill sales at $2.7 billion — well above the $1.7 billion consensus. SB1 Markets turned more bullish, lifting its target to 350 kroner with a buy recommendation.

A separate presentation highlighted CagriSema, the combination therapy that suffered a setback early this year when it underperformed against Eli Lilly's Zepbound in a head-to-head trial. New data from the REDEFINE-1 programme now cover body composition, muscle strength, and cardiovascular risk. The US FDA is reviewing a marketing application, with a decision expected in 2026.

Beyond the obesity wars, Novo notched a clinical win in a rare-disease programme. Its phase 3 HIBISCUS study tested Etavopivat against sickle cell anaemia. The drug cut painful vaso-occlusive crises by 27 percent compared with placebo. The median time to the first crisis stretched to roughly 38 weeks in the treated group, versus nearly 21 weeks for controls. Almost half of patients on the drug showed improved haemoglobin levels. Novo plans to file for regulatory approval of the sickle cell therapy in the second half of the year.

The US market is also opening a new distribution channel for its diabetes drug. Amazon's online pharmacy now stocks the Ozempic tablet, offering same-day delivery to customers. Amazon already carries the Wegovy injectable.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

The management team has nudged its full-year guidance slightly higher, now targeting a revenue and profit decline of between 4 and 12 percent — a marginal improvement from the previous forecast. The stock recently traded at €40.53, having gained nearly 26 percent over the past month, though it remains roughly 9 percent lower year to date.

Analysts remain split. TD Cowen rates the shares a "Hold" with a $42 price target. The next major catalyst arrives on August 5, when Novo Nordisk releases first-half results. The Istanbul congress runs until May 15, with a head-to-head data comparison between oral semaglutide and Lilly's Orforglipron scheduled for the final day — a session that could further shape the market share narrative. European approval of the Wegovy pill is expected before year-end, with the first international launches pencilled in for the second half of 2026.

Ad

Novo Nordisk Stock: New Analysis - 13 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69323870 |